Manish A Shah1, Erin B Kennedy2, Daniel V Catenacci3, Dana C Deighton4, Karyn A Goodman5, Narinder K Malhotra6, Christopher Willett7, Brendon Stiles1, Prateek Sharma8, Laura Tang9, Bas P L Wijnhoven10, Wayne L Hofstetter11. 1. New York Hospital/Weill Cornell Medical Center, New York, NY. 2. American Society of Clinical Oncology, Alexandria, VA. 3. University of Chicago Medicine, Chicago, IL. 4. Alexandria, VA. 5. Icahn School of Medicine at Mount Sinai, New York, NY. 6. Yolanda G. Barco Cancer Institute, Meadville, PA. 7. Duke Cancer Center, Durham, NC. 8. University of Kansas School of Medicine and VAMC, Kansas City, KS. 9. Memorial Sloan Kettering Cancer Center, New York, NY. 10. Erasmus University Medical Center, Rotterdam, the Netherlands. 11. The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with locally advanced esophageal cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the more recently published literature (1999-2019) on therapy options for patients with locally advanced esophageal cancer and provide recommended care options for this patient population. RESULTS: Seventeen randomized controlled trials met the inclusion criteria. Where possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma. RECOMMENDATIONS: Multimodality therapy for patients with locally advanced esophageal carcinoma is recommended. For the subgroup of patients with adenocarcinoma, preoperative chemoradiotherapy or perioperative chemotherapy should be offered. For the subgroup of patients with squamous cell carcinoma, preoperative chemoradiotherapy or chemoradiotherapy without surgery should be offered. Additional subgroup considerations are provided to assist with implementation of these recommendations. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with locally advanced esophageal cancer. METHODS:ASCO convened an Expert Panel to conduct a systematic review of the more recently published literature (1999-2019) on therapy options for patients with locally advanced esophageal cancer and provide recommended care options for this patient population. RESULTS: Seventeen randomized controlled trials met the inclusion criteria. Where possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma. RECOMMENDATIONS: Multimodality therapy for patients with locally advanced esophageal carcinoma is recommended. For the subgroup of patients with adenocarcinoma, preoperative chemoradiotherapy or perioperative chemotherapy should be offered. For the subgroup of patients with squamous cell carcinoma, preoperative chemoradiotherapy or chemoradiotherapy without surgery should be offered. Additional subgroup considerations are provided to assist with implementation of these recommendations. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
Authors: Farshid Dayyani; Brian R Smith; Ninh T Nguyen; Shaun Daly; Marcelo W Hinojosa; Steven N Seyedin; Jeffrey Kuo; Jason B Samarasena; John G Lee; Thomas H Taylor; May T Cho; Maheswari Senthil Journal: Future Oncol Date: 2022-05-23 Impact factor: 3.674